10565-15-8

Upstream product

• 5344-78-5 4-bromo-3-nitroanizole 
• 105-53-3 diethyl malonate 
• 10298-80-3 2-chloro-5-methoxynitrobenzene 
• 996-82-7 sodium diethylmalonate 

Downstream Products

• 83089-27-4 2-(4-methoxy-2-nitrophenyl)propane-1,3-diol 
• 108274-39-1 ethyl 2-(4-methoxy-2-nitrophenyl)acetate 
• 89553-54-8 C₁₃H₁₄N₂O₃S 
• 79035-22-6 Methanesulfonic acid 3-methanesulfonyloxy-2-(4-methoxy-2-nitro-phenyl)-propyl ester 
• 1050514-12-9 2-(4-methoxy-2-nitrophenyl)ethylmethylsulfone 
• 1050514-02-7 2-(4-methoxy-2-nitrophenyl)ethanol 
• 1050514-03-8 4-methoxy-1-(2-methoxyethyl)-2-nitrobenzene 
• 1050514-11-8 4-methoxy-1-[2-(methylthio)ethyl]-2-nitrobenzene 
• 1050514-10-7 1-(2-bromoethyl)-4-methoxy-2-nitrobenzene 
• 3416-18-0 5-hydroxyoxindole 
• 20876-30-6 (4-methoxy-2-nitro-phenyl)-acetic acid 
• 7699-19-6 6-methoxyoxindole 

Relevant academic research and scientific papers

LRRK2 INHIBITORS

Provided herein are compounds that inhibit or partially inhibit the activity of leucine rich repeat kinases. Also provided herein are methods of treatment of CNS disorders comprising administration of inhibitors of leucine rich repeat kinases.

Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors

A series of N-benzylated isatin oximes were developed as inhibitors of the mitogen-activated kinase, JNK3. X-ray crystallographic structures aided in the design and synthesis of novel, selective compounds, that inhibit JNK3, but not p38 MAP kinase and provided key insights into understanding the behavior of gatekeeper residue methionine-146 in determining target selectivity for this series.

QUINOXALINE COMPOUNDS AND USE THEREOF

The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors

The present invention is directed to a class indolinone compounds, hexahydro-cyclohepta-pyrrole oxindoles, which are useful as protein kinase inhibitors.

A general oxindole synthesis

A general synthesis of indol-2(3H)-ones (oxindoles), was developed based on the addition of dimethyl malonate to commercially available halonitrobenzenes. The advantage of this route over many other oxindole syntheses was the regiochemical control of the substitution pattern on the aromatic ring.